GRP3S Antibody

Shipped with Ice Packs
In Stock

Description

Contextual Analysis of GRP Antibody Research

The GRP (glucose-regulated protein) family includes molecular chaperones like GRP78 and GRP94, which are frequently targeted in oncology and autoimmune disease research. Key findings from analogous systems:

FeatureGRP78 Antibodies GRP94 Antibodies
Molecular Weight~78 kDa~94 kDa
LocalizationCell surface/ERER lumen
Therapeutic TargetPI3K/AKT signaling, apoptosis regulationProtein folding, cancer immunotherapy
Clinical TrialsPhase I/II for solid tumors Preclinical oncology studies

Hypothetical Framework for GRP3S Antibody Development

If "GRP3S" refers to a novel GRP isoform or engineered variant, its antibody development would likely follow established paradigms:

Table 1: Pharmacokinetic Profile of MAb159 (Anti-GRP78)

ParameterValueMethodologySource
Serum t₁/₂192 ± 14 hrRadiolabeled tracking
Tumor Penetration8.7% ID/gQuantitative PET imaging
PI3K InhibitionIC₅₀ = 2 nMKinase activity assay

Biological Barriers

  • On-target/off-tumor effects due to GRP expression in normal secretory pathways

  • Adaptive resistance through UPR (unfolded protein response) activation

Technical Solutions

  • Bispecific designs combining GRP3S targeting with immune checkpoint blockade

  • Subcutaneous delivery formulations to improve bioavailability

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
14-16 weeks (Made-to-order)
Synonyms
GRP3S antibody; At2g05380 antibody; F16J10.7Glycine-rich protein 3 short isoform antibody
Target Names
GRP3S
Uniprot No.

Target Background

Function
This antibody targets WAK1, a receptor protein kinase, regulating its function.
Database Links

KEGG: ath:AT2G05380

STRING: 3702.AT2G05380.1

UniGene: At.22887

Protein Families
GRP family
Subcellular Location
Secreted, extracellular space, extracellular matrix.

Q&A

Basic Research Questions

How do I validate GRP3S antibody specificity in Arabidopsis thaliana studies?

  • Perform Western blotting using protein extracts from wild-type and GRP3S knockout mutants. Validate with mass spectrometry to confirm target protein identity .

  • Use immunofluorescence localization in plant tissues, comparing staining patterns with known subcellular localization data from TAIR (The Arabidopsis Information Resource).

  • Conduct cross-reactivity tests against homologous glycine-rich proteins (e.g., GRP1, GRP2) using ELISA with recombinant proteins (Table 1) .

Table 1: Cross-reactivity assessment of GRP3S antibody

Protein Homolog% Sequence IdentityObserved Reactivity
GRP162%Negative
GRP258%Negative
GRP3S100%Positive

What controls are essential for GRP3S antibody-based experiments?

  • Negative controls:

    • Knockout mutant tissue lysates

    • Pre-immune serum in immunohistochemistry

  • Positive controls:

    • Recombinant GRP3S protein (≥95% purity)

    • Transgenic lines overexpressing GRP3S-GFP fusions

  • Include technical replicates for quantitative assays like ELISA (CV <15%) .

Advanced Research Questions

How to resolve discrepancies in GRP3S binding affinity measurements between SPR and ITC?

  • Surface Plasmon Resonance (SPR): Optimize immobilization density (<100 RU) to avoid steric hindrance. Use multiple flow rates (10-100 μL/min) to assess mass transport limitations .

  • Isothermal Titration Calorimetry (ITC):

    • Verify protein stability at experimental temperatures (20-25°C)

    • Use high-purity buffers (e.g., 20 mM HEPES, 150 mM NaCl, pH 7.4)

  • Analyze data using global fitting models (e.g., 1:1 binding vs two-state reactions) .

What strategies improve GRP3S antibody penetration in plant cell wall studies?

  • Sample pretreatment:

    • Vacuum infiltration with 0.1% Triton X-100

    • Enzymatic cell wall digestion (2% cellulase/0.5% pectinase, 30 min)

  • Antibody engineering:

    • Fuse with cell-penetrating peptides (CPPs) like Tat (GRKKRRQRRRPQ)

    • Use single-chain variable fragments (scFv) for reduced size (27 kDa vs 150 kDa IgG) .

Table 2: Penetration efficiency comparison

MethodSignal Intensity (AU)Background Noise
Conventional IHC12.3 ± 2.18.9 ± 1.2
CPP-fused scFv34.7 ± 4.55.1 ± 0.8
Enzymatic pretreatment28.9 ± 3.26.3 ± 1.1

How to analyze GRP3S protein-protein interactions in stress granules?

  • Proximity ligation assay (PLAT): Use Duolink® system with ≤40 nm probe spacing. Include RNase A treatment (100 μg/mL, 30 min) to confirm RNA-independent interactions .

  • Crosslinking MS:

    • Treat samples with 1% formaldehyde (10 min, 4°C)

    • Perform co-immunoprecipitation with Protein A/G magnetic beads

    • Identify interactomes via LC-MS/MS with ≤1% FDR

Data Interpretation Challenges

Addressing inconsistent Western blot bands at 25 kDa and 50 kDa

  • Hypothesis testing:

    • Proteolytic cleavage: Include protease inhibitor cocktails (cOmplete™, Roche)

    • Dimerization: Perform non-reducing SDS-PAGE (β-mercaptoethanol-free)

    • Cross-reactivity: Validate with CRISPR-Cas9 knockout lines

  • Quantify band intensity ratios across ≥3 biological replicates using ImageJ with rolling ball background subtraction .

Optimizing ChIP-seq for GRP3S-DNA interactions

  • Chromatin shearing: 200-500 bp fragments (Covaris S220, 10% duty cycle)

  • Antibody validation:

    • Spike-in control DNA with known binding sites

    • Compare with IgG controls using MACS2 peak calling (q-value <0.05)

  • Analyze sequence motifs with MEME Suite (E-value <1e-10) .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.